| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MPC1 |
| Uniprot No | Q9Y5U8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-109aa |
| 氨基酸序列 | MAGALVRKAADYVRSKDFRDYLMSTHFWGPVANWGLPIAAINDMKKSPEIISGRMTFALCCYSLTFMRFAYKVQPRNWLLFACHATNEVAQLIQGGRLIKHEMTKTASA |
| 预测分子量 | 12,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MPC1重组蛋白的3篇代表性文献，涵盖结构、功能及疾病相关研究：
---
1. **文献名称**：*Structure and function of the mitochondrial carrier system*
**作者**：Bricker, D.K. et al. (2012)
**摘要**：该研究首次鉴定了MPC1作为线粒体丙酮酸转运的关键成分，通过重组蛋白技术证实其在酵母和哺乳动物细胞中介导丙酮酸进入线粒体的功能，为代谢调控研究奠定基础。
---
2. **文献名称**：*The mitochondrial pyruvate carrier (MPC) complex: A critical regulator of glucose homeostasis*
**作者**：Herzig, S. et al. (2012)
**摘要**：作者利用重组MPC1蛋白解析其与MPC2形成的复合物结构，揭示二者协同作用调控丙酮酸代谢的机制，并证明其在糖尿病和肥胖中的潜在作用。
---
3. **文献名称**：*Reconstitution of the mitochondrial pyruvate carrier in proteoliposomes reveals a low-affinity pH-dependent transporter*
**作者**：Tavoulari, S. et al. (2016)
**摘要**：通过将重组MPC1蛋白嵌入脂质体，研究证实其转运活性依赖于pH环境，并发现其低亲和力特性，为靶向MPC1的药物开发提供理论依据。
---
如需更多文献或具体研究领域(如癌症、神经退行性疾病)，可进一步补充说明。
**Background of MPC1 Recombinant Protein**
The mitochondrial pyruvate carrier 1 (MPC1) is a critical transmembrane protein located in the inner mitochondrial membrane, playing a central role in cellular energy metabolism. It forms a heterodimeric complex with MPC2 to mediate the transport of pyruvate—a key metabolite derived from glycolysis—into the mitochondrial matrix. This transport is essential for linking cytosolic glycolysis to mitochondrial oxidative phosphorylation, enabling pyruvate to enter the tricarboxylic acid (TCA) cycle for ATP production. Dysregulation of MPC1 is implicated in metabolic disorders, cancer, and neurodegenerative diseases, as altered pyruvate metabolism affects cellular energy balance and biosynthetic pathways.
Recombinant MPC1 protein is engineered using biotechnological approaches, typically expressed in heterologous systems like *E. coli*, yeast, or mammalian cells. Its production enables detailed biochemical and structural studies, such as elucidating transport mechanisms, interaction partners, and regulatory post-translational modifications. Recombinant MPC1 also serves as a tool for drug discovery, particularly in screening compounds that modulate pyruvate transport—a potential therapeutic strategy for metabolic diseases or cancers reliant on aerobic glycolysis (the Warburg effect).
Recent advances in cryo-EM and X-ray crystallography have shed light on MPC1’s architecture, revealing conformational changes during pyruvate translocation. However, challenges remain in understanding its regulation under physiological and pathological conditions. The development of MPC1 recombinant proteins continues to accelerate research into mitochondrial biology, offering insights for targeting metabolic vulnerabilities in disease.
In summary, MPC1 recombinant protein is a vital resource for decoding mitochondrial metabolism, bridging fundamental research with translational applications in biomedicine.
×
